BACKGROUND: Certolizumab pegol is the third anti- @entity310 agent approved by the Food and Drug Administration of the United States. AIM: To provide a comprehensive up-to-date review of the efficacy and safety of certolizumab in @entity30 ( @entity30 ). METHODS: Electronic databases, including PubMed, EMBASE, the Cochrane library and the Science Citation Index, were searched to retrieve relevant trials. In addition, meeting abstracts and the reference lists of retrieved articles were reviewed for further relevant studies. RESULTS: Three trials, enrolling a total of 1040 @entity1 , are included in the meta-analysis to evaluate the short-term efficacy of certolizumab, which is effective for rapid induction and long-term maintenance of clinical response or remission and can improve quality of life in @entity1 with @entity30 . Certolizumab is also effective for @entity1 who have lost response to infliximab. However, its efficacy in infliximab-exposed @entity1 is probably less than in infliximab-naive @entity1 . Re-induction with certolizumab in @entity1 who have flared on maintenance therapy can rescue a significant proportion of @entity1 . There is no significant association between the efficacy of certolizumab and the baseline C-reactive protein level. In comparison with placebo, certolizumab does not increase the risk of serious adverse events. CONCLUSIONS: Certolizumab is effective and safe in treating @entity30 . Further studies are still required to assess its full safety profile.

Meta-analysis: the efficacy and safety of certolizumab pegol in XXXX .

@entity310 :: ('7124', 'Gene') :: ['TNF-alpha'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity30 :: ('MESH:D003424', 'Disease') :: ['CD', "Crohn's disease"]
@entity30 :: (MESH:D003424,Disease) :: ['Crohn's disease']
